Linhai Tianyu Pharmaceutical is an API manufacturer based in China. It holds 11 active US drug master files across a filed portfolio of 9 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 15 September 2023 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3013345425 |
| Molecule | Regulators | Docs |
|---|---|---|
| Azilsartan Medoxomil | US FDA | 2 |
| Valsartan | US FDA | 2 |
| Apixaban | US FDA | 1 |
| Dapagliflozin | US FDA | 1 |
| Febuxostat | US FDA | 1 |
| Montelukast | US FDA | 1 |
| Sacubitril | US FDA | 1 |
| Ticagrelor | US FDA | 1 |
| Vildagliptin | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Review its manufacturing sites and inspection history in PharmaDB.
Sign up freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.